Actively Recruiting
Phase 2 Study of Maintenance Therapy Using Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Patients With High-Risk Multiple Myeloma After Stem Cell Transplant
Led by Emory University · Updated on 2025-09-02
34
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
This research aims to evaluate the effects of a combination therapy using belantamab mafodotin, pomalidomide, and dexamethasone in patients with high-risk myeloma. The trial focuses on patients who have undergone autologous stem cell transplant and achieved at least a partial response. This phase II study intends to assess the complete response rates and safety of this combined treatment approach for high-risk myeloma patients. Participants receive belantamab mafodotin intravenously over 30 minutes on day 1 of every other 28-day cycle, pomalidomide orally once daily on days 1 through 21, and dexamethasone orally once daily on days 1, 8, 15, and 22. Treatment cycles repeat every 28 days unless disease progression or unacceptable side effects occur. After completing treatment, patients are followed up every three months. During the study, participants will undergo regular assessments to monitor response to treatment, including complete response rates and other measures of tumor activity. Safety and tolerability will be closely evaluated through adverse event monitoring. Follow-up visits every three months after treatment completion will continue to track progression-free survival, overall survival, duration of response, and other outcomes for up to three years.
CONDITIONS
Brief Title
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Research Team
A
Ajay K. Nooka, MD,MPH,FACP
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
